Evidence map›Paper›PMID 33447845›Full record

ArticleEuropean heart journal2021

Heart failure drug treatment: the fantastic four.

Johann Bauersachs

Registry-linked trialAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05580510 ("An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"), which is not on this map. Cited by 142 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05580510 phase2 / phase3unknown statusstarted 2023, after this paper: background citation

"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"

Ran2023Enrolled160Registered outcomes9Posted comparisons0ConditionsCongenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection FractionArmsEmpagliflozin 10 MG OD, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
PMID 30415601PMID 30520545PMID 32865377PMID 33030857PMID 33186500PMID 33832352PMID 33960724PMID 34447992PMID 26787434PMID 26787728other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. [Impact of cardiovascular diseases on fitness to drive: mobility limitations in the elderly].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2024
    Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Johann BauersachsDepartment of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Heart FailurePharmaceutical PreparationsBenzhydryl CompoundsGlucosidesHumansNeprilysinBenzhydryl CompoundsempagliflozinGlucosidesNeprilysinPharmaceutical Preparations

Identifiers

PMID33447845
PMCPMC7878007

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.